Tyler Menichiello
Tyler Menichiello is a contributing editor to Bioprocess Online, Cell & Gene, and Clinical Leader. He interviews executives and subject matter experts across the biopharma industry to write about their successful approaches in biologics development from pre-IND planning all the way through trial design, manufacturing, and commercialization. He aims to investigate the industry’s most prevalent challenges and emerging best practices to provide both interesting and actionable content for industry leaders. Prior to writing for Life Science Connect, Tyler spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, where he worked on clinical trials involving hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can email Tyler at tyler.menichiello@lifescienceconnect.com, or visit his LinkedIn profile.
ARTICLES BY TYLER MENICHIELLO
-
![DNA molecule-GettyImages-2148124383]( "Discovery vs. Hypothesis-Driven Cell Line Development")
Discovery vs. Hypothesis-Driven Cell Line Development10/8/2024Susan Sharfstein, Ph.D., explains how discovery-driven research can further our understanding of cellular biology and ultimately inform cell line development.
-
![GettyImages-1480892977-doctor-gene-dna-brain-lungs-heart]( "How Platform Technologies Are Shaping The Gene Therapy Landscape")
How Platform Technologies Are Shaping The Gene Therapy Landscape9/30/2024Leading experts in gene therapy discuss CMC strategy for platform technologies, product lifecycle management, and the role CDMOs play in moving the space forward.
-
![GettyImages-1414998744-scientist-checklist-clipboard-autoclave]( "Gene Therapy CMC Experts On Late-Stage Process Changes")
Gene Therapy CMC Experts On Late-Stage Process Changes9/27/2024At the 2024 Bioprocessing Summit, a panel of CMC experts spoke about the challenges commercializing gene therapies, specifically focusing on considerations for late-stage process changes.
-
![AI artificial intelligence, cyber security-GettyImages-1998660059]( "Considerations For AI Use In Biomanufacturing")
Considerations For AI Use In Biomanufacturing9/18/2024Expert's from this month's Bioprocess Online Live event discuss different use cases for AI and shared their thoughts on the adoption of these technologies.
-
![Explaining the human brain-GettyImages-1554047481]( "Delivering Large Molecules To The CNS, Overcoming The Blood-Brain Barrier")
Delivering Large Molecules To The CNS, Overcoming The Blood-Brain Barrier8/29/2024Aliada Therapeutics' CSO, John Dunlop, Ph.D., explains the company's blood-brain barrier-crossing delivery platform for large molecules.
-
![laptop diary day planner-GettyImages-648963774]( "Key Takeaways From The 2024 Bioprocessing Summit")
Key Takeaways From The 2024 Bioprocessing Summit8/26/2024Editor Tyler Menichiello reflects on the topics and trends covered at this year's Bioprocessing Summit in Boston.
-
![Programming, learning Artificial intelligence isometric robot-GettyImages-2148984216]( "Integrating Analytics And Automation In Cell Therapy Manufacturing")
Integrating Analytics And Automation In Cell Therapy Manufacturing7/31/2024Experts from last month’s Cell & Gene Live event discuss practical ways to utilize emerging technologies.
-
![teamwork-GettyImages-1363884154]( "The Patchwork Of Outsourced ADC Manufacturing")
The Patchwork Of Outsourced ADC Manufacturing7/29/2024Antibody-drug conjugate (ADC) manufacturing is complicated, to say the least, and it relies on a diversity of expertise. In a recent Bioprocess Online Live event, Chief Editor Matt Pillar talks with expert panelists about how this unique modality requires unique manufacturing considerations.
-
![GettyImages-1388560078-chimeric-antigen-receptor-cell]( "Manufacturing CAR-T In Vivo")
Manufacturing CAR-T In Vivo7/25/2024Manufacturing chimeric antigen receptor (CAR) T-cell therapies is a costly and complicated process. Interius BioTherapeutics is on a mission to reduce this complexity and get these therapies to patients faster — by manufacturing CAR T/NK cells in patients' bodies.
-
![doctor holding syringe-GettyImages-1446843578]( "The Path To Producing An Insulin Biosimilar")
The Path To Producing An Insulin Biosimilar7/17/2024I met with rBIO co-founder and president, Cameron Owen, as well as its CSO, Dr. Deenadayalan Bakthavatsalam, to learn about what it takes to develop an insulin biosimilar. They candidly told me about the company’s plan of execution, as well as how challenging it is to scale-up manufacturing to a commercial level (in the ballpark of several metric tons per year for insulin) — which is the company’s primary focus right now.
